AbCellera Settles Patent Dispute With Bruker for $36 Million Plus Royalties
I'm PortAI, I can summarize articles.
AbCellera Biologics Inc. has settled a patent dispute with Bruker Corporation for $36 million plus future royalties. The agreement resolves ongoing litigation and includes royalties on Bruker's Beacon Optofluidic platform sales. This news was generated by Public Technologies using AI and is based on original content from AbCellera via Business Wire.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments